Treatment of men with erectile dysfunction with transurethral alprostadil

New England Journal of Medicine

Volumn 336, Issue 1, 1997, Pages 1-7

  Padma Nathan, Harin ^a,b   Hellstrom, Wayne J G ^c   Kaiser, Fran E ^d   Labasky, Richard F ^e   Lue, Tom F ^f   Nolten, Wolfram E ^g   Norwood, Paul C ^h   Peterson, Craig A ⁱ   Shabsigh, Ridwan ^j   Tam, Peter Y ⁱ   Place, Virgil A ⁱ   Gesundheit, Neil ⁱ   Cowley, Christy ⁱ   Nemo, Kerry J ⁱ   Spivack, Alfred P ⁱ   Stephens, Darby E ⁱ   Todd, Leslie K ⁱ  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b Male Clinic   (United States)

^c TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF UTAH   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

^g UNIVERSITY OF WISCONSIN MADISON   (United States)

^h Peachwood Medical Group   (United States)

ⁱ Menlo Park and VIVUS   (United States)

^j NewYork Presbyterian Columbia University Irving Medical Center   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

PROSTAGLANDIN E1;

ADULT; AGE; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETES MELLITUS; DOUBLE BLIND PROCEDURE; DRUG DELIVERY SYSTEM; DRUG EFFICACY; HOME CARE; HUMAN; HYPOTENSION; IMPOTENCE; INJURY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PAIN; PENIS ERECTION; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEXUAL INTERCOURSE; URETHRA; VASCULAR DISEASE;

ADULT; AGED; AGED, 80 AND OVER; ALPROSTADIL; COITUS; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION ROUTES; HUMANS; IMPOTENCE; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; TREATMENT OUTCOME; URETHRA;

EID: 8044251513     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJM199701023360101     Document Type: Article

References (40)

1. NIH Consensus Development Panel on Impotence. Impotence. JAMA 1993;270:83-90.
2. Krane RJ, Goldstein I, Saenz de Tejada I. Impotence. N Engl J Med 1989;321;1648-59.
3. Feldman HA, Goldstein I, Hatzichristou DG, Krane RJ, McKinlay JB. Impotence and its medical and psychosocial correlates: results of the Massachusetts Male Aging Study. J Urol 1994;151:54-61.
4. Morley JE, Kaiser FE. Impotence: the internist's approach to diagnosis and treatment. Adv Intern Med 1993;38:151-68.
5. Yohimbine for male sexual dysfunction. Med Lett Drugs Ther 1994;36: 115-6.
6. Morales A. Nonsurgical management options in impotence. Hosp Pract 1993;28:15-6, 19-20, 23-4.
7. Meinhardt W, Lycklama a Nijeholt AAB, Kropman RF, Zwartendijk J. The negative pressure device for erectile disorders: when does it fail? J Urol 1993;149:1285-7.
8. Broderick GA, McGahan JP, Stone AR, White RD. The hemodynamics of vacuum constriction erections: assessment by color Doppler ultrasound. J Urol 1992;147:57-61.
9. Cookson MS, Phillips DL, Huff ME, Fitch WP III. Analysis of microsurgical penile revascularization results by etiology of impotence. J Urol 1993;149:1308-12.
10. Rossi D, Rattier C, Belicar M, et al. Les prosthèses de verge gonflables: expérience à propos de 58 implantations. Prog Urol 1993;3:796-802.
11. Bejany DE, Perito PE, Lustgarten M, Rhamy RK. Gangrene of the penis after implantation of penile prosthesis: case reports, treatment recommendations and review of the literature. J Urol 1993;150:190-2.
12. Montague DK. Periprosthetic infections. J Urol 1987;138:68-9.
13. Ishii N, Watanabe H, Irisawa C, et al. Intracavernous injection of prostaglandin E1 for the treatment of erectile impotence. J Urol 1989;141: 323-5.
14. Kerfoot WW, Carson CC. Pharmacologically induced erections among geriatric men. J Urol 1991;146:1022-4.
15. Lakin MM, Montague DK, VanderBrug Medendorp S, Tesar L, Schover LR. Intracavernous injection therapy: analysis of results and complications. J Urol 1990;143:1138-41.
16. Linet OI, Ogrinc FG. Efficacy and safety of intracavernosal alprostadil in men with erectile dysfunction. N Engl J Med 1996;334:873-7.
17. Padma-Nathan H, Goldstein I, Payton T, Krane RJ. Intracavernosal pharmacotherapy: the pharmacologic erection program. World J Urol 1987;5:160-5.
18. Virag R, Shoukry K, Floresco J, Nollet F, Greco E. Intracavernous self-injection of vasoactive drugs in the treatment of impotence: 8-year experience with 615 cases. J Urol 1991;145:287-93.
19. Waldhauser M, Schramek P. Efficiency and side effects of prostaglandin E1 in the treatment of erectile dysfunction. J Urol 1988;140:525-7.
20. Levine SB, Althof SE, Turner LA, et al. Side effects of self-administration of intracavernous papaverine and phentolamine for the treatment of impotence. J Urol 1989;141:54-7.
21. Lehmann EL. Nonparametrics: statistical methods based on ranks. San Francisco: Holden-Day, 1975.
22. Efron B, Tibshirani RJ. An introduction to the bootstrap. New York: Chapman & Hall, 1993.
23. Fleiss JL. Statistical methods for rates and proportions. 2nd ed. New York: John Wiley, 1981.
24. Hedlund H, Andersson K-E. Contraction and relaxation induced by some prostanoids in isolated human penile erectile tissue and cavernous artery. J Urol 1985;134:1245-50.
25. Lue TF, Tanagho EA. Physiology of erection and pharmacological management of impotence. J Urol 1987;137:829-36.
26. Steers WD. Neural control of penile erection. Semin Urol 1990;8:66-79.
27. Rajfer J, Aronson WJ, Bush PA, Dorey FJ, Ignarro LJ. Nitric oxide as a mediator of relaxation of the corpus cavernosum in response to nonadrenergic, noncholinergic neurotransmission. N Engl J Med 1992;326:90-4.
28. Lue TF, Tanagho EA. Functional anatomy and mechanism of penile erection. In: Tanagho EA, Lue TF, McClure RO, eds. Contemporary management of impotence and infertility. Baltimore: Williams & Wilkins, 1988: 39-50.
29. Lue TF. Physiology of erection and pathophysiology of impotence. In: Walsh PC, Retik AB, Stamey TA, Vaughan ED Jr, eds. Campbell's urology. 6th ed. Vol. 1. Philadelphia: W.B. Saunders, 1992:709-28.
30. Roy AC, Adaikan PG, Sen DK, Ratnam SS. Prostaglandin 15-hydroxydehydrogenase activity in human penile corpora cavernosa and its significance in prostaglandin-mediated penile erection. Br J Urol 1989;64: 180-2.
31. Palmer LS, Valcic M, Melman A, Giraldi A, Wagner G, Christ GJ. Characterization of cyclic AMP accumulation in cultured human corpus cavernosum smooth muscle cells. J Urol 1994;152:1308-14.
32. Trigo-Rocha F, Hsu GL, Donatucci CF, Martinez-Pineiro L, Lue TF, Tanagho EA. Intracellular mechanism of penile erection in monkeys. Neurourol Urodyn 1994;13:71-80.
33. Paoletti R. Biochemistry and pharmacology of prostaglandin E1: introductory remarks. In: Sinzinger H, Rogatti W, eds. Prostaglandin E1 in atherosclerosis. New York: Springer-Verlag, 1986:3-7.
34. Hamberg M, Samuelsson B. On the metabolism of prostaglandins E 1 and E 2 in the guinea pig. J Biol Chem 1972;247:3495-502.
35. Idem. On the metabolism of prostaglandins E 1 and E 2 in man. J Biol Chem 1971;246:6713-21.
36. van Ahlen H, Peskar BA, Sticht G, Hertfelder HJ. Pharmacokinetics of vasoactive substances administered into the human corpus cavernosum. J Urol 1994;151:1227-30.
37. Wolfson B, Pickett S, Scott NE, DeKernion JB, Rajfer J. Intraurethral prostaglandin E-2 cream: a possible alternative treatment for erectile dysfunction. Urology 1993;42:73-5.
38. Cavallini G. Minoxidil versus nitroglycerin: a prospective double-blind controlled trial in transcutaneous erection facilitation for organic impotence. J Urol 1991;146:50-3.
39. Kim ED, McVary KT. Topical prostaglandin-E1 for the treatment of erectile dysfunction. J Urol 1995;153:1828-30.
40. von Heyden B, Donatucci CF, Kaula N, Lue TF. Intracavernous pharmacotherapy for impotence: selection of appropriate agent and dose. J Urol 1993;149:1288-90.